Lexagene Holdings Inc. has released the voting results for election of its board of directors at the annual general and special meeting of shareholders held on Sept. 12, 2017, in Vancouver. The director nominees as listed in the information circular dated Aug. 1, 2017, were elected as directors of the company at the meeting to serve until the next annual general meeting.

Names of directors: Dr. Jack Regan, Daryl Rebeck, Tom Slezak, Dr. Eric Olsen and Dr. Manohar Furtado.

All of the other matters put forward before shareholders for consideration and approval at the meeting, as described in the circular, were duly approved.

Also, the company announces that it has granted to Dr. Furtado, a new director, and newly hired consultants of the company, stock options to purchase up to 270,000 common shares at a price of $1.05 per common share vesting 10 per cent on the grant date and 15 per cent every six months thereafter expiring on March 12, 2021. In addition, the company granted 315,000 restricted share units (RSU) to these individuals. The RSU trigger date is March 12, 2018, and expiry date Sept. 12, 2020. The options and RSU have been granted in accordance with the terms of the company’s current omnibus plan.

We seek Safe Harbor.